Hessekiel Jeffrey 4

What Happened
Jeffrey Hessekiel, Chief Legal & Administrative Officer of Cytokinetics (CYTK), received annual equity awards on 2026-03-15 totaling 51,791 shares/equivalents: 20,646 restricted stock units (RSUs) and two sets of stock options for 8,325 and 22,820 shares, respectively. All items are reported as acquired at $0.00 per unit (these are grant entries, not open‑market purchases or sales). These awards are compensation grants, not immediate cash receipts or dispositions.

Key Details

• Transaction date: 2026-03-15; Form 4 filed 2026-03-17 (appears filed within the regulatory two-business-day window).
• Grants reported:
  • 20,646 RSUs (footnote F1) — recorded $0.00 per share.
  • 8,325 stock options (footnote F2) — recorded $0.00 per option (derivative).
  • 22,820 stock options (footnote F3) — recorded $0.00 per option (derivative).
• Shares/ownership after the transaction: not specified in the provided filing excerpt.
• Plan: Awards subject to the company’s Amended and Restated 2004 Equity Incentive Plan (per footnotes).

Context

• RSUs convert 1:1 to common shares and vest over three years (40% at year 1, 40% at year 2, 20% at year 3), subject to continued employment (F1).
• The stock options vest in 48 equal monthly installments, subject to continued employment (F2, F3). As option grants, they are derivative rights to acquire shares upon vesting/exercise — not immediate share ownership.
• These are routine annual compensation awards for an executive and do not by themselves indicate a purchase or sale signal.